Tirzepatide

OBJECTIVE: To explore adverse drug events (ADEs) associated with tirzepatide using real-world data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database to guide its safe management. METHODS: ADE reports from th…

Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack of data evaluating the types of reactions associated wit…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Ad…

OBJECTIVE: No meta-analysis has been published comparing the efficacy and safety of tirzepatide vs once-daily basal insulins in subjects with type 2 diabetes (T2D) inadequately controlled with oral anti-hyperglycemic drugs. This meta-analysis was con…

INTRODUCTION: Thyroid nodules are common and require vigilant monitoring due to malignancy potential. They become particularly concerning in patients using glucagon-like peptide (GLP-1) analogs, which are associated with a proposed increased risk of…

INTRODUCTION: Tirzepatide, a dual GIP/GLP-1 receptor agonist, is highly effective in reducing body weight and improving glucometabolic outcomes. However, most clinical trials have overlooked the role of diet quality, leaving unclear whether lifestyle…

INTRODUCTION: Cardiovascular diseases remain the leading cause of mortality worldwide. Tirzepatide is approved for the treatment of type 2 diabetes mellitus and overweight and is increasingly used. The adverse effects with tirzepatide may not be dise…

INTRODUCTION: This study assessed whether early weight loss following tirzepatide treatment was associated with clinical characteristics and outcomes at 52 weeks in Japanese patients with type 2 diabetes (T2D). METHODS: Post hoc analyses used pooled…

Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM). However, the optimal tirzepatide dose following a switch from 1.0 mg of semaglutid…

INTRODUCTION: Approximately 3-5% of patients with endometrial cancer (EC) are diagnosed under the age of 40 years, with 70% of these individuals being nulliparous. Consequently, fertility-sparing treatment for eligible young patients with endometrial…

OBJECTIVE: Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a pot…

Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is a promising therapeutic option for type 2 diabetes mellitus (T2DM). Nevertheless, its effect and underlying mecha…

This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications…

BACKGROUND: GLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and obesity management. Recent pharmacovigilance reports have raised concerns about potential neuropsychiatric adverse events, yet comprehensive safety assessment…

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus. We report a case of acute mesenteric ischemia in a patient following treatmen…

BACKGROUND: Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function…